Chartwell Investment Partners, LLC Viridian Therapeutics, Inc.\De Transaction History

Chartwell Investment Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$22.57 - $29.67 $135,442 - $178,049	6,001 Added 17.86%	39,600 $942,000
Q1 2023 Apr 14, 2023	SELL	$25.04 - $37.6 $687,423 - $1.03 Million	-27,453 Reduced 44.97%	33,599 $855,000
Q4 2022 Feb 15, 2023	BUY	$18.78 - $29.74 $65,504 - $103,733	3,488 Added 6.06%	61,052 $1.78 Million
Q3 2022 Oct 27, 2022	BUY	$10.7 - $25.5 $615,934 - $1.47 Million	57,564 New	57,564 $1.18 Million

181

76.7M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.